

Mats Heyman Karolinska University Hospital Eugeniavagen 3 171 64 Solna SWEDEN

21.10.2024 nr RKU-4/82

## **DECISION**

to grant authorisation for clinical trial on the basis of Regulation (EU) No 536/2014 of the European Parliament and of the council

State Agency of Medicines has received the application from sponsor Karolinska University Hospital on 12.09.2024 to conduct a clinical trial under the conditions stipulated in Regulation (EU) No 536/2014 art 5 (1) and § 99¹ (1) of Estonian Medicinal Products Act (MPA).

Based on art 8 of Regulation (EU) No 536/2014, considering the aspects covered by Part I and Part II of the assessment report, on the basis of § 99<sup>6</sup> section 1 p 1 and (3) of Medicinal Product Act

State Agency of Medicines has decided to give the approval to conduct the clinical study protocol no ALLTogether1 under the following conditions:

**protocol no**: ALLTogether1 (Master Protocol Version 5.0, dated 14.04.2023)

**full title of the trial**: ALLTogether1 - A Treatment Study Protocol of the ALLTogether Consortium for Children and Young Adults (0-45 Years of Age) with Newly Diagnosed Acute Lymphoblastic Leukaemia (ALL)

**sponsor of the trial**: Karolinska University Hospital

number of subjects in Estonia: 90

## principal investigators and study locations:

- Dr Mari Punab, Tartu University Hospital, L. Puusepa tn 1a, 50406 Tartu, Estonia
- Dr Kristi Lepik, Tallinn Children's Hospital Foundation, Tervise tn 28, 13419 Tallinn, Estonia
- Dr Katrin Palk, North Estonia Medical Centre Foundation, J. Sütiste tee 19, 13419 Tallinn, Estonia

The addressee may file a challenge with State Agency of Medicines within 30 days as of the day when the addressee became or should have become aware of the decision as prescribed in Code of Administrative Procedure § 71(1). If the addressee wishes to have the decision to annulled by the administrative court, he or she may submit a complaint to the Tartu

Administrative Court as prescribed in § 7(1) and § 46(1) of the Code of Administrative Court Procedure within 30 days after the date on which the decision was notified to the applicant.

(digitally signed)

Katrin Kiisk Director General